Western Wealth Management LLC Increases Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Western Wealth Management LLC lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,623 shares of the medical equipment provider’s stock after purchasing an additional 103 shares during the quarter. Western Wealth Management LLC’s holdings in Intuitive Surgical were worth $1,222,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Liberty Capital Management Inc. grew its holdings in Intuitive Surgical by 3.8% during the fourth quarter. Liberty Capital Management Inc. now owns 815 shares of the medical equipment provider’s stock worth $275,000 after acquiring an additional 30 shares during the period. Miracle Mile Advisors LLC grew its holdings in Intuitive Surgical by 2.3% in the fourth quarter. Miracle Mile Advisors LLC now owns 1,438 shares of the medical equipment provider’s stock valued at $485,000 after purchasing an additional 32 shares during the period. Ausdal Financial Partners Inc. grew its holdings in Intuitive Surgical by 1.5% in the fourth quarter. Ausdal Financial Partners Inc. now owns 2,192 shares of the medical equipment provider’s stock valued at $739,000 after purchasing an additional 33 shares during the period. Venturi Wealth Management LLC grew its holdings in Intuitive Surgical by 10.7% in the fourth quarter. Venturi Wealth Management LLC now owns 341 shares of the medical equipment provider’s stock valued at $115,000 after purchasing an additional 33 shares during the period. Finally, Modera Wealth Management LLC grew its holdings in Intuitive Surgical by 2.0% in the third quarter. Modera Wealth Management LLC now owns 1,715 shares of the medical equipment provider’s stock valued at $501,000 after purchasing an additional 34 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $366.34 on Friday. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76. The company has a market cap of $129.85 billion, a price-to-earnings ratio of 66.13, a PEG ratio of 5.78 and a beta of 1.36. The business’s 50 day moving average price is $386.84 and its 200 day moving average price is $343.10.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a return on equity of 13.27% and a net margin of 27.16%. The firm had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter last year, the business posted $1.00 earnings per share. The firm’s revenue was up 11.5% compared to the same quarter last year. On average, analysts predict that Intuitive Surgical, Inc. will post 4.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on ISRG shares. Truist Financial raised their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. Raymond James raised their price objective on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a report on Thursday, January 25th. Barclays lifted their price target on Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Citigroup lifted their price target on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, Robert W. Baird lowered their price target on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a research note on Friday. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $396.17.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, VP Fredrik Widman sold 5,041 shares of Intuitive Surgical stock in a transaction on Friday, March 15th. The stock was sold at an average price of $397.07, for a total value of $2,001,629.87. Following the sale, the vice president now owns 110 shares in the company, valued at $43,677.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Intuitive Surgical news, VP Fredrik Widman sold 5,041 shares of Intuitive Surgical stock in a transaction on Friday, March 15th. The stock was sold at an average price of $397.07, for a total value of $2,001,629.87. Following the sale, the vice president now owns 110 shares in the company, valued at $43,677.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the completion of the sale, the senior vice president now owns 1,842 shares in the company, valued at approximately $736,800. The disclosure for this sale can be found here. Insiders have sold 248,418 shares of company stock worth $95,927,097 over the last quarter. 0.90% of the stock is currently owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.